Price
Frequently asked questions
What is MorphoSys's market capitalization?
What is the Earnings Per Share (EPS) for MorphoSys?
What are the analyst ratings and target price for MorphoSys's stock?
What is MorphoSys's revenue over the trailing twelve months?
What is the EBITDA for MorphoSys?
What is the free cash flow of MorphoSys?
What is the 5-year beta of MorphoSys's stock?
How many employees does MorphoSys have, and what sector and industry does it belong to?
What is the free float of MorphoSys's shares?
Financials
Market Cap
$2.70B5Y beta
0.73EPS (TTM)
-$13.28Free Float
1.07MRevenue (TTM)
$195.20MEBITDA (TTM)
-$548.83MFree Cashflow (TTM)
-$320.70MPricing
Analyst Ratings
The price target is $59.09 and the stock is covered by 11 analysts.
Buy
4
Hold
7
Sell
0
Information
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
446
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker